

# Development of New Spectrophotometric Methods for the Simultaneous Estimation of Levosalbutamol Sulphate and Beclomethasone Dipropionate in Bulk Drug and Pharmaceutical Formulations(ROTACAP)

Lakshmi Prasanna.B\*, Sathish Kumar Shetty.A\*\*, PriyatamNadh.T,  
Gopinath. B, Manzoor Ahmed

Department of Pharmaceutical Analysis, National College of Pharmacy, BalarjUrs Road, Shimoga (District), Karnataka, India – 577 201.

**\*\*Corres. Author : drskshetty@rediffmail.com  
Cell: 09019376434, Fax:08182 273796.**

**Abstract:** Two simple, precise and accurate UV methods have been developed for the simultaneous estimation of Levosalbutamol sulphate (LS) and Beclomethasone dipropionate (BD) in bulk and pharmaceutical formulation. Method A applied Area Under Curve (AUC) for the analysis of LS in the wavelength range of 272-282nm and for BD in the wavelength range of 234-244nm. Method B is Q-absorbance method based on the measurement of absorptivity at 269nm (as an iso-absorptive point) and 277 nm. LS and BD shows a maximum absorption at 277nm and 239nm respectively with a linearity range of 10-50 µg/ml and 5-25 µg/ml respectively for both the methods. Results of analysis were statistically validated with recovery studies and were found to be satisfactory.

**Keywords:** Levosalbutamol sulphate, Beclomethasone dipropionate, Area under curve, Q-value analysis.

## INTRODUCTION

Levosalbutamol Sulphate is an orally inhaled  $\beta_2$ -adrenoreceptor agonist, indicated for the relief of bronchospasm in conditions such as asthma and chronic obstructive pulmonary disease (COPD).<sup>[1]</sup> It is chemically (R)-1-(4-hydroxy-3-hydroxy-methyl phenyl)-2-(ter-butylamino)ethanol sulphate<sup>[2]</sup> (Figure:1). Levosalbutamol is a single isomer  $\beta_2$ -adrenoreceptor agonist that differs from racemic Salbutamol by elimination of (S)-Salbutamol. Clinical and mechanistic studies have demonstrated that (R)-Salbutamol alone provides the  $\beta_2$ -agonist activity that is needed for the relief of broncho constriction.

Evidence from clinical studies shows delayed recovery from exacerbation of asthma by patients who are


exposed to high concentrations of (S)-Salbutamol. Thus, when compared with racemic salbutamol, clinically comparable bronchodilation can be achieved with doses that substantially decrease  $\beta$ -mediated side effects.<sup>[3]</sup>

Beclomethasone dipropionate is an orally inhaled adrenocortico-steroid which suppresses bronchial inflammation, increases peak expiratory flow rate, reduces need for rescue  $\beta_2$ -agonist inhalations and prevents episodes of acute asthma. It is chemically 9 $\alpha$ -chloro-11 $\beta$ -hydroxy-16 $\beta$ -methyl-3, 20-dioxo-1, 4-pregnadiene-17, 21-diyldipropionate (Figure:2). When administered via inhalation, there is an extensive conversion of Beclomethasone dipropionate to active metabolite Beclomethasone-17-monopropionate within the lungs prior to systemic


absorption. [4] It is an official drug Indian pharmacopoeia 1996, [5] United states pharmacopoeia 2004 [6] and British Pharmacopoeia 2003. [7]

The combination of Levosalbutamol sulphate and Beclomethasone Dipropionate is very useful in the treatment of asthmatic bronchoconstriction.

Literature survey reveals that, only few spectrophotometric [8-11] and bio-analytical methods by LC-MS and HPLC were found using human plasma [12-14], urine [15], blood [16] and biological fluids [17] for the quantitative estimation of Levosalbutamol sulphate and Beclomethasone Dipropionate in bulk and pharmaceutical formulations have been developed. Hence an attempt has been made to develop new UV methods for its estimation in bulk and pharmaceutical formulation with good accuracy, simplicity and precision.



**Figure 1: Chemical Structure of Levosalbutamol sulphate**



**Figure 2: Chemical Structure of Beclomethasone dipropionate**

## EXPERIMENTAL

### Materials and Method

Pure sample of both the drugs were obtained from Cipla, Sikkim, India as gift samples. A Shimadzu UV-1700 UV/VIS Spectrophotometer was used with 1cm match quartz cell. Rotacaps of 400 µg of Levosalbutamol sulphate and 200 µg of Beclomethasone dipropionate were procured from local pharmacy.


### Preparation of Standard solution

Both the pure drugs of about 50mg were weighed accurately and dissolved in 50ml of redistilled ethanol to give the standard stock solution of 1000µg/ml (Stock A). Aliquots of standard stock solution were pipetted out and suitably diluted with ethanol to get a final concentration of the standard solution.

### Method A: Area Under Curve method (AUC)

The AUC method involves the calculation of integrated value of absorbance with respect to the wavelength between two selected wavelengths 272 nm and 282nm for LS (Figure:3) and 234 nm and 244 nm for BD (Figure:4). Area calculation processing item calculates the area bound by the curve and the horizontal axis. The horizontal axis is selected by entering the wavelength range over which the area has to be calculated. The wavelength range is selected on the basis of repeated observation so as to get the linearity between area under curve and concentration. Suitable dilutions of Stock A of the both the drugs were prepared and scanned in the spectrum mode in the wavelength range 400-200nm and the calibration curve was plotted (Figure: 6,7).

As the results obtained were satisfactory, the methods were applied for the pharmaceutical formulations.



**Figure 3: Spectra for LS at 272-282 nm in ethanol by AUC**




Figure 4: Spectra for BD at 234-244nm in ethanol by AUC




Figure 5: Isoabsorptive point of Levosalbutamol sulphate and Beclomethasone dipropionate at 269 nm.




Figure 6: Calibration curve of for Levosalbutamol sulphate at 272–282 nm in ethanol by Area Under Curve method.




Figure 7: Calibration curve of Beclomethasone dipropionate at 234-244 nm in ethanol by Area Under Curve method.

#### Determination of Maximum Wavelength and Iso-absorptive point

By appropriate dilution of two standard drug solutions with ethanol, solutions containing 50 µg/ml of Levosalbutamol sulphate and 25 µg/ml of Beclomethasone dipropionate were scanned separately in the range of 200–400 nm to determine the wavelength of maximum absorption for both the drugs. Levosalbutamol sulphate showed absorbance maxima at 277 nm ( $\lambda_1$ ) and 229 nm and Beclomethasone dipropionate showed maxima absorbance at 239 nm ( $\lambda_2$ ). The overlain spectra showed  $\lambda_{max}$  of both drugs and also iso-absorptive points at 269 nm (Figure 5).

#### Method B: Q-Analysis Method or Absorption Ratio Method

From the overlain spectrum of Levosalbutamol sulphate and Beclomethasone dipropionate (Figure 5), two wavelengths were selected one at 269 nm which

is isoabsorptive point for both the drugs and the other is 277 nm  $\lambda_{max}$  of Levosalbutamol sulphate. Suitable dilutions of Stock A of the drug were prepared and scanned in the spectrum mode in the wavelength range 400–200 nm and the absorbance ratio values for both the drugs at selected wavelengths were also calculated.

#### Preparation and analysis of the rotacap formulation


Twenty capsules were chosen and tapped so as to accumulate all the contents in the capsule body. Capsules were opened carefully and their contents were emptied into a 50 ml volumetric flask and dissolved in 25 ml ethanol and the content was kept in ultrasonicator for 20 min. Finally the volume was made up to the mark with ethanol. The solution was filtered through Whatmann filter paper No.41 and this solution was used as stock A solution.

From the above stock A solution, 3.5 ml of the aliquot


was pipetted out and was transferred to a 10 ml volumetric flask. The volume was made up to 10 ml with ethanol to obtain a solution with final concentration of LS and BD, 56  $\mu\text{g/ml}$  and 28  $\mu\text{g/ml}$  respectively. Six replicates were prepared and analysed at the selected analytical wavelengths, were statistically validated

#### Validation of the methods<sup>[18]</sup>

All the methods were validated according to ICH guidelines by carrying out analysis of six replicate samples of tablet. Recovery studies were carried out at three different levels i.e. 80%, 100% and 120% by adding the pure drug to previously analyzed tablet powder sample. From the amount of drug found, percentage recovery was calculated (Table 1).



**Figure 8: Calibration curve of Levosalbutamol sulphate and Beclomethasone dipropionate at 269 nm in ethanol by Q-Absorption ratio method.**



**Figure 9: Calibration curve of Levosalbutamol sulphate and Beclomethasone dipropionate at 277 nm in ethanol by Q-Absorption ratio method.**

**Table 1: Optical characteristics and other parameters for Method A**

| Parameters   | Levosabutamol sulphate | Beclomethasone dipropionate |
|--|------------------------|-----------------------------|
| $\lambda_{\max}$ / wavelength range (nm)                         | 272 - 282              | 234 - 244                   |
| Linearity range ( $\mu\text{g/ml}$ )                             | 10-50                  | 5-25                        |
| Molar absorbtivity (litre, mole <sup>-1</sup> cm <sup>-1</sup> ) | 237                    | 51.16                       |
| Coefficient of Correlation                                       | 0.9995                 | 0.9995                      |
| Slope* (m)   | 0.0041                 | -0.0006                     |
| Intercept* (c)   | 0.0014                 | -0.0003                     |
| Accuracy (%RSD)  |                        |                             |
| 80%  | 0.5163                 | 0.3593                      |
| 100%   | 0.6278                 | 0.2516                      |
| 120%   | 0.2804                 | 0.2804                      |
| 120%   |                        | 0.5123                      |
| Precision (%RSD)   |                        |                             |
| Intra-day  | 0.8788                 | 0.3867                      |
| Inter-day  | 0.9827                 | 0.6262                      |
| LOD  | 0.3082                 | 0.4054                      |
| LOQ  | 0.9340                 | 4.0540                      |

\* $y = mx + c$ ; when x is the concentration in  $\mu\text{g/ml}$  and y is absorbance unit.

**Table 1: Optical characteristics and other parameters for Method B**

| Parameters   | Levosabutamol sulphate | Beclomethasone dipropionate |
|--|------------------------|-----------------------------|
| Wavelength range (nm)  | 277                    | 277                         |
| Iso-absorptive point (nm)  | 269                    | 269                         |
| Linearity range ( $\mu\text{g/ml}$ )                             | 10-50                  | 5-25                        |
| Molar absorbtivity (litre, mole <sup>-1</sup> cm <sup>-1</sup> ) | 12.85                  | 26.83                       |
| Coefficient of Correlation                                       | 0.9995                 | 0.9992                      |
| Slope* (m)   | 0.0051                 | 0.0095                      |
| Intercept* (c)   | 0.005                  | 0.0049                      |
| Accuracy (%RSD)  |                        |                             |
| 80%  | 0.275                  | 0.297                       |
| 100%   | 0.201                  | 0.201                       |
| 120%   | 0.284                  | 0.290                       |
| Precision (%RSD)   |                        |                             |
| Intra-day  | 0.5736                 | 0.3867                      |
| Inter-day  | 1.106                  | 0.7694                      |
| LOD  | 0.5039                 | 0.0168                      |
| LOQ  | 1.5271                 | 0.0511                      |

**Table 2: Results of formulation**

| METHOD | Brand Name | Label claim of LS ( $\mu\text{g}$ ) | Label claim of BD ( $\mu\text{g}$ ) | Amount found for LS ( $\mu\text{g}$ ) | Amount found for BD ( $\mu\text{g}$ ) | %Recovery $\pm$ SD**for LS | %Recovery $\pm$ SD**for BD |
|--------|------------|-------------------------------------|-------------------------------------|---------------------------------------|---------------------------------------|----------------------------|----------------------------|
| A      | Aerocort   | 400                                 | 200                                 | 398.8                                 | 198.5                                 | 99.71 $\pm$ 0.8199         | 99.2 $\pm$ 0.3881          |
| B      |            | 400                                 | 200                                 | 369.9                                 | 199.0                                 | 99.41 $\pm$ 0.8333         | 99.5 $\pm$ 0.1910          |

\*\*Average of six determinations

## RESULTS AND DISCUSSION

The estimation of Levosalbutamol sulphate and Beclomethasonedipropionate in rotacaps formulation was found to be accurate and reproducible with a linearity of 10-50  $\mu\text{g}/\text{ml}$  and 5-25  $\mu\text{g}/\text{ml}$  respectively for both the methods and the correlation coefficient 0.999 and 0.998 for the methods A and B respectively. The optical characteristics such as linearity range, molar absorptivity, percentage relative standard deviation of recovery studies and precision in each method were calculated and the results were reported in Table 1. Also the regression characteristics like slope (m), intercept (c) and correlation coefficient (r) were calculated and are presented in Table 1. The accuracy of the methods was a different levels i.e. 80%, 100% and 120%. The values of standard deviation were satisfactory and the recovery studies

were close to 100%. The %RSD value was less than 2, an indicative of the accuracy of the methods.

## CONCLUSION

Thus, it can be concluded that the methods developed in the present investigation were simple, sensitive, accurate, rapid and precise. Hence, the above said methods can be successfully applied for the estimation of Levosalbutamol sulphate and Beclomethasone dipropionate in pharmaceutical formulation.

## ACKNOWLEDGEMENT

We would like to thank Cipla, Sikkim, India for providing reference sample of Levosalbutamol sulphate and Beclomethasonedipropionate to facilitate this work.

## REFERENCES

- Gilman AG and Limbird LE editor., Goodman and Gilman's the pharmacological Basis of Therapeutics, New York and McGraw Hill, 2001, 11, 720.
- <http://www.en.wiki.en.wikipedia.org/wiki/Levosalbutamol>
- Milgrom H., Levosalbutamol in the treatment of asthma, Expert Opin Pharmacother 2006., Aug, 7(12), 1659-1668.
- Block JH, Beale JM., Wilson and Gisvold's text book of medicinal and pharmaceutical chemistry, 11<sup>th</sup> ed. London (UK), Lippincott Williams & Wilkins, 2002, 812-814.
- The controller of publications, New Delhi, Govt. of India, Indian Pharmacopoeia, Vol. I, 1996, 32.
- United States Pharmacopoeia 27, NF 22, Washington D.C, United States Pharmacopoeial Convention, Inc, 2004, 211.
- British Pharmacopoeia, London, Medicines and Health care Products regulatory agency (MHRA), Vol. I, 2003, 196.
- Dave HN, Mashru RC, Thakkar AR, Simultaneous determination of salbutamol sulphate, bromhexine hydrochloride and etofylline in pharmaceutical formulations with the use of four rapid derivative spectrophotometric methods, Anal Chem Acta, 2007, Jul 30, 597(1), 113-120.
- Basavaiah K, Somashekar BC, Ramakrishna V, Rapid titrimetric and spectrophotometric methods for salbutamol sulphate in pharmaceuticals using N-bromosuccinimide, Acta Pharm, 2007 Mar, 57(1), 87-98.
- Arun K, Mishra, Manoj Kumar, Amrita Mishra, Anurag Verma, Pronobesh Chattopadhyay, Validated UV spectroscopic method for estimation of salbutamol from tablet formulations, Arch of App Sci, 2010, 2(3), 207-211.
- Thulasamma P, Kishore Kumar R, Venkateswarulu, Development of new spectrophotometric methods for the estimation of Levosalbutamol in tablet dosage forms, Analytical chemistry, 2009, 8(4).

12. Fuyu Guan, Cornelius Uboh, Lawrence Soma, Anne Hess, Yi Lu, Deborah Tsang S,  
Sensitive liquid chromatographic/tandem mass spectrometric method for the determination of Beclomethasone Dipropionate and its metabolites in equine plasma and urine, *J Mass Spectrom*, 2003 Aug, 38(8), 823-838.
13. GhulamMurtaza, Mahmood Ahmad, Muhammad AsadullahMadni, Muhammad WaheedAsghar, A new reverse phase HPLC method with fluorescent detection for the determination of Salbutamol sulphate in human plasma, *Bull ChemSoc Ethiop*, 2009, 23(1), 1-8.
14. McCarthy PT, Atwal S, Sykes AP, Ayres JG, Measurement of terbutaline and salbutamol in plasma by high performance liquid chromatography with fluorescence detection, *Biomed Chromatogr*, 1993 Jan/Feb, 7(1), 25-28.
15. De Groof J, Degroodt JM, Wyhowski de Bukanshi B, Beernaert H, Salbutamol identification in liver and urine by high performance thin layer chromatography and densitometr., *Z LebensmUntersForsch*, 1991 Aug, 193(2), 126-129.
16. Black SB, HanssonRC, Determination of Salbutamol and detection of other  $\beta$ -agonists in humanposmortem whole blood and urine by GC-MS-SIM, *J Anal Toxicol*, 1999, 23, 113-118.
17. Girault J, Istin B, Malgouyat JM, Brisson AM, Fourtillan JB, Simultaneous determination of Beclomethasone, Beclomethasonemonopropionate and Beclomethasonedipropionate in biological fluids using a particle beam interface for combining liquid chromatography with negative-ion chemical ionization mass spectrometry, *J Chromatogr B*, 1991 Mar 8, 564(1), 43-53.
18. ICH, Harmonised Tripartite Guideline, Text on Validation of Analytical Procedures, International Conference on Harmonization, Geneva, October 1994, 1-5.

\*\*\*\*\*